Christoph B Olivier’s Team Explores Platelet Reactivity and Fibrin Clot-Strength in AF
Jan Hartmann, Chief Medical Officer at Haemonetics, reposted from Haemonetics on LinkedIn:
”Encouraging progress in personalized cardiovascular care.
A recent paper from Christoph B Olivier’s team at my alma mater, The University of Freiburg, explores “Platelet Reactivity and Fibrin Clot-Strength as assessed by TEG in Patients with Atrial Fibrillation undergoing Percutaneous Coronary Intervention”.
Their findings suggest that combined high platelet reactivity and increased platelet–fibrin clot strength after the PCI may elevate ischemic risk—though neither factor alone was predictive.
This aligns with data in broader post-PCI populations, with or without AFib:
- Young-Hoon Jeong, MD, PhD’s team (European Heart Journal, 2024) in South Korea showed that patients with combined platelet-fibrin clot strength and high platelet reactivity had the highest risk for MACE post-PCI (more than patients with either factor alone).
- A 2023 study from Fudan University in China reported similar results, where “a combination of high fibrinogen and HRPR may identify recurrent adverse ischemic events over 12 months.”
It’s encouraging to see continued momentum toward individualized post-intervention strategies, especially in tailoring OAC and antiplatelet therapy.
References:
Read the full article here.
Article: Platelet Reactivity and Fibrin Clot-Strength as assessed by TEG in Patients with Atrial Fibrillation undergoing Percutaneous Coronary Intervention
Authors: Diona Gjermeni, Hannah Vetter, Sofia Szabó, Viktoria Anfang, Carina Juelch, Stefan Leggewie, David Hesselbarth, Markus Jäckel, Daniel Duerschmied, Dietmar Trenk, Dirk Westermann, Christoph B Olivier
Stay updated on all scientific advances in the field of thrombosis with Hemostasis Today.
-
Aug 11, 2026, 16:44The Evolving Treatment Landscape of Hemophilia: From Factor Replacement to Gene Therapy
-
Aug 11, 2026, 16:34Advancing Hemophilia Care Through Training and Local Capacity Building – WFH
-
Aug 11, 2026, 16:26Sabrina H.: The Spectrum of PF4-Mediated Thrombotic Disorders
-
Aug 11, 2026, 16:17Mandy Lauw: From CRTH Training to Clinical Trials
-
Aug 11, 2026, 16:05Obi Light Ogbonnia: From 52 Years of Living With Sickle Cell to a Global Stage
-
Aug 11, 2026, 15:42Iva Pruner: Hemostasis, Thrombosis, and a Little Death Metal
-
Aug 11, 2026, 15:25Bradley Maron։ The AI Revolution in Cardiovascular Drug Development
-
Aug 11, 2026, 15:10Jared Rice: When a Negative DAT Doesn’t Mean the Alloimmune Risk Is Gone
-
Aug 11, 2026, 14:58Manuel De Jesus: Validating the Future of Point-of-Care Anemia Monitoring